A prometabolite strategy inhibits cardiometabolic disease in an ApoE–/– murine model of atherosclerosis
Butyrate, a microbiome-derived short-chain fatty acid with pleiotropic effects on inflammation and metabolism, has been shown to significantly reduce atherosclerotic lesions, rectify routine metabolic parameters such as low-density lipoprotein cholesterol (LDL-C), and reduce systemic inflammation in...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society for Clinical investigation
2025-08-01
|
| Edice: | JCI Insight |
| Témata: | |
| On-line přístup: | https://doi.org/10.1172/jci.insight.191090 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
